secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002072
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports preliminary ARCALYST revenue of $122.5M for FY2022; cash $190.4M
--------------------------------------------------------------------------------

- ARCALYST net revenue Q4 2022 $39.9M, full-year $122.5M (unaudited).
- Year-end 2022 cash, equivalents and ST investments $190.4M, funding into at least 2025.
- Greater than 800 prescribers for recurrent pericarditis; 22% have prescribed for 2+ patients.
- Payer approval rate >90%; approx 45% of patients who discontinued ARCALYST restarted therapy.
- KPL-404 Phase 2 RA trial: 2 of 3 cohorts enrolled; proof-of-concept data expected 1H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/tm232503d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer